Description:
As in vitro diagnostic (IVD) testing returns to its vital role in healthcare, it remains a cornerstone in medical practice, providing crucial insights for physicians, from diagnosis to precision medicine. While COVID-19 testing sees a decline, it continues to influence total revenues for 2023. In this ever-changing landscape, characterized by new products, shifts in global health spending, regulatory updates, and evolving disease trends, IVD remains resilient.
Kalorama Information’s IVD Trends and Market Update: November 2023 is your definitive guide to the latest market trends and insights. This report, updated by Kalorama’s analysts in Q3 2023, offers the most current information on the IVD market.
Key Market Segments:
- Point-of-Care
- Next-Generation Sequencing (NGS)
- Cancer Testing
- Companion Diagnostics
- Immunochemistry
- Mass Spectrometry
- Gene Testing
- Molecular Diagnostics
Highlighted Trends in Q3 2023:
- Proliferation of Multiplex Testing
- Adoption of AI Technologies
Why Choose Kalorama Information:
Kalorama Information is renowned for its in-depth analysis of the IVD market, thanks to the expertise of its authors and its commitment to delivering precise and timely data.
Discover:
- What’s Driving Growth in the IVD Market in Q3 and the Second Half of 2023
- Major Trends Affecting the Market in Q3 and the Second Half of 2023
- Impact of COVID-19 on the Market in Q3 and the Second Half of 2023
- Product Trends and New Developments Shaping the IVD Market in the Second Half of 2023
Stay Informed, Stay Competitive:
As the IVD market evolves, it’s crucial to stay informed. Kalorama’s IVD Trends and Market Update: November 2023 provides the insights you need to navigate this dynamic industry. Order your copy today to stay ahead of the curve.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: COVID-19 Product Sales, by Segment, 2023 ($ millions)
| Segment | 2023 | %Mkt |
| COVID-19 Lab-based Immunoassay Sales (Antigen & Serology) | $XX Million | XX% |
| COVID-19 Lab-based Molecular Sales | $XX Million | XX% |
| COVID-19 Rapid Sales (POC Professional and POC At-Home) | $XX Million | XX% |
| Total COVID-19 | $XX Million | XX% |
Re-evaluated October 2023
Source: Kalorama Information
